Clinical Trial Update: SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial update evaluating SHR-1210 with trastuzumab, oxaliplatin, and capecitabine as neoadjuvant therapy for gastric adenocarcinoma/gastroesophageal ju…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• SHR-1210 (camrelizumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Gastric Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING